Identification of a panel of sensitive and specific DNA methylation markers for squamous cell lung cancer
Open Access
- 10 July 2008
- journal article
- research article
- Published by Springer Nature in Molecular Cancer
- Vol. 7 (1) , 62
- https://doi.org/10.1186/1476-4598-7-62
Abstract
Background: Lung cancer is the leading cause of cancer death in men and women in the United States and Western Europe. Over 160,000 Americans die of this disease every year. The five-year survival rate is 15% – significantly lower than that of other major cancers. Early detection is a key factor in increasing lung cancer patient survival. DNA hypermethylation is recognized as an important mechanism for tumor suppressor gene inactivation in cancer and could yield powerful biomarkers for early detection of lung cancer. Here we focused on developing DNA methylation markers for squamous cell carcinoma of the lung. Using the sensitive, high-throughput DNA methylation analysis technique MethyLight, we examined the methylation profile of 42 loci in a collection of 45 squamous cell lung cancer samples and adjacent non-tumor lung tissues from the same patients.Results: We identified 22 loci showing significantly higher DNA methylation levels in tumor tissue than adjacent non-tumor lung. Of these, eight showed highly significant hypermethylation in tumor tissue (p < 0.0001): GDNF, MTHFR, OPCML, TNFRSF25, TCF21, PAX8, PTPRN2 and PITX2. Used in combination on our specimen collection, this eight-locus panel showed 95.6% sensitivity and specificity.Conclusion: We have identified 22 DNA methylation markers for squamous cell lung cancer, several of which have not previously been reported to be methylated in any type of human cancer. The top eight markers show great promise as a sensitive and specific DNA methylation marker panel for squamous cell lung cancer.This publication has 65 references indexed in Scilit:
- Identification of a panel of sensitive and specific DNA methylation markers for lung adenocarcinomaMolecular Cancer, 2007
- DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients – Technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology groupEuropean Journal Of Cancer, 2007
- Computed Tomography Screening and Lung Cancer OutcomesPublished by American Medical Association (AMA) ,2007
- Cancer Statistics, 2007CA: A Cancer Journal for Clinicians, 2007
- Cytosine Methylation Profiles as a Molecular Marker in Non–Small Cell Lung CancerCancer Research, 2006
- Survival of Patients with Stage I Lung Cancer Detected on CT ScreeningNew England Journal of Medicine, 2006
- CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancerNature Genetics, 2006
- Promoter methylation of genes in bronchial lavages: A marker for early diagnosis of primary and relapsing non-small cell lung cancer?Lung Cancer, 2005
- CpG island methylation and expression of tumour-associated genes in lung carcinomaEuropean Journal Of Cancer, 2005
- Impact of low-dose CT on lung cancer screeningLung Cancer, 2004